Welcome to our dedicated page for CALCIMEDICA news (Ticker: CALC), a resource for investors and traders seeking the latest updates and insights on CALCIMEDICA stock.
CalciMedica, Inc. (Nasdaq: CALC) is a clinical-stage biopharmaceutical company developing calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. Its news flow is driven by clinical trial progress, preclinical publications, regulatory interactions, financing activities, and scientific presentations related to its lead CRAC channel inhibitor Auxora™ and other pipeline candidates.
Investors following CALC news can expect regular updates on the Phase 2 KOURAGE trial of Auxora in patients with acute kidney injury (AKI) with associated respiratory failure, including disclosures about enrollment status, study design details, and anticipated data timing. CalciMedica also issues press releases on publications in peer-reviewed journals such as the American Journal of Nephrology and JCI Insight, which describe preclinical and translational data supporting CRAC channel inhibition in AKI and pulmonary arterial hypertension.
Another key news theme is the company’s acute pancreatitis (AP) program. CalciMedica reports on its discussions with the U.S. Food and Drug Administration regarding the design of a pivotal trial in AP and on collaborations, such as its agreement with Telperian, to apply artificial intelligence to completed Auxora trials and external datasets to refine trial design and patient selection. Conference participation and medical meeting symposia, including events focused on AKI, critical care nephrology, and pancreatitis, also feature prominently in the company’s announcements.
In addition, CalciMedica’s news releases cover quarterly financial results, cash runway commentary, equity offering updates, and corporate governance developments such as equity incentive plan amendments and board composition. For readers tracking CALC, this news page provides a consolidated view of operational milestones, scientific developments, and capital markets activity that shape the company’s clinical-stage trajectory in inflammatory and immunologic diseases.
CalciMedica, a clinical-stage biopharmaceutical company specializing in CRAC channel inhibition therapies, announced that CEO Rachel Leheny, Ph.D., will present at two upcoming healthcare investment conferences on July 15, 2024. The events include the H.C. Wainwright 3rd Annual Kidney Virtual Conference at 11:00 AM ET/8:00 AM PT and the JonesTrading Healthcare Seaside Summit at 1:15 PM ET/10:15 AM PT. Live webcasts of these presentations will be available on CalciMedica's Investor Relations website and will be archived for 90 days.
CalciMedica, a biopharmaceutical company specializing in CRAC channel inhibition therapies for inflammatory and immunologic illnesses, announced its inclusion in the Russell Microcap® Index. The inclusion will be effective from July 1, 2024, following the Russell U.S. Indexes annual reconstitution, which ranks the 4,000 largest U.S. stocks by market capitalization. This marks a significant milestone for CalciMedica, highlighting its growth since going public in Q1 2023. Russell indexes are key benchmarks for investment managers and institutional investors, representing $10.5 trillion in assets as of December 2023.
CalciMedica announced positive topline data from its Phase 2b CARPO trial evaluating Auxora™ in treating acute pancreatitis (AP) with accompanying systemic inflammatory response syndrome (SIRS). The trial met its primary objective, showing a statistically significant dose response. Key findings include up to a 43.6% reduction in median time to solid food tolerance, a 61.7% reduction in severe organ failure, and a 100% reduction in hospital stays longer than 21 days. The trial demonstrated Auxora's safety and tolerability, with plans for a Phase 3 trial and an upcoming FDA meeting.
CalciMedica announced it will host a conference call on June 27, 2024, at 8:30 a.m. ET to discuss topline data from its Phase 2b CARPO trial of Auxora in acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS). The clinical-stage biopharmaceutical company focuses on developing CRAC channel inhibition therapies for inflammatory and immunologic illnesses. Interested parties can join the call via a live webcast or dial-in numbers provided on CalciMedica's investor relations website. A webcast replay will be available post-event.
CalciMedica reported a significant quarter ending March 31, 2024, marked by the completion of enrollment for the Phase 2b CARPO trial for Auxora™ in acute pancreatitis (AP), with topline data expected in 2Q 2024.
Additionally, the KOURAGE Phase 2 trial for severe acute kidney injury (AKI) will start patient enrollment in 2Q 2024, with data expected in 2025. A related abstract will be presented at Digestive Disease Week (DDW) 2024.
Financially, the company completed a $54 million private placement, with $20.4 million received upfront and $33.1 million pending from warrant exercises. With $25.7 million in cash and equivalents, operations are funded into the second half of 2025. Total operating losses were $5.8 million for Q1, offset by a $5.6 million gain from warrant liability adjustment, resulting in a $0.1 million net income.
CalciMedica Inc. announces an upcoming presentation at Digestive Disease Week 2024 where collaborators from Cedars-Sinai will present human proteomics data supporting the potential benefits of Auxora™ in severe acute pancreatitis. The presentation will highlight the similarities between the benefits of Auxora and those seen in COVID-19 pneumonia.
FAQ
What is the current stock price of CALCIMEDICA (CALC)?
What is the market cap of CALCIMEDICA (CALC)?
